Phaseline

Companies › Bracco Diagnostics

Bracco Diagnostics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 4, 1 Phase 2; Neurology, Cardiovascular, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sulfur Hexafluoride Lipid Type A Microspheres (Lumason)
Ultrasound contrast agent
–Phase 3Heart Diseases; Trauma Abdomen; Hydrocephalus in InfantsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06400004Sulfur Hexafluoride Lipid Type A Microspheres (Lumason)Phase 3Heart DiseasesCardiovascularDec 2026
NCT03490929Sulfur Hexafluoride Lipid Type A Microspheres (Lumason)Phase 4Trauma AbdomenOtherDec 2026
NCT06693752Sulfur Hexafluoride Lipid Type A Microspheres (Lumason)Phase 2Hydrocephalus in InfantsNeurologySep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CSPC Mingfule Pharmaceutical (Guangzhou) Epygenix RHEACELL GmbH & Co. KG Shenzhen Ausa Pharmed Tenax Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.